New drug cocktail shows promise for tough head and neck cancers
NCT ID NCT00076310
First seen Apr 21, 2026 · Last updated Jun 13, 2026 · Updated 14 times
Summary
This study tested whether adding the targeted drug Tarceva to two standard chemotherapy drugs (cisplatin and docetaxel) could shrink tumors in people with head and neck cancer that had spread or come back. 50 adults with this advanced cancer took part. The goal was to see how well the combination worked and how safe it was.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.